CA2715486A1 - Composition for modulating stem cell growth with prostaglandins - Google Patents

Composition for modulating stem cell growth with prostaglandins Download PDF

Info

Publication number
CA2715486A1
CA2715486A1 CA2715486A CA2715486A CA2715486A1 CA 2715486 A1 CA2715486 A1 CA 2715486A1 CA 2715486 A CA2715486 A CA 2715486A CA 2715486 A CA2715486 A CA 2715486A CA 2715486 A1 CA2715486 A1 CA 2715486A1
Authority
CA
Canada
Prior art keywords
alkyl
hydroxy
cyclo
halogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2715486A
Other languages
English (en)
French (fr)
Inventor
Ryuji Ueno
Sachiko Kuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CA2715486A1 publication Critical patent/CA2715486A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2715486A 2008-02-19 2009-02-19 Composition for modulating stem cell growth with prostaglandins Abandoned CA2715486A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2971308P 2008-02-19 2008-02-19
US61/029,713 2008-02-19
PCT/JP2009/053474 WO2009104807A1 (en) 2008-02-19 2009-02-19 Composition for modulating stem cell growth with prostaglandins

Publications (1)

Publication Number Publication Date
CA2715486A1 true CA2715486A1 (en) 2009-08-27

Family

ID=40602552

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2715486A Abandoned CA2715486A1 (en) 2008-02-19 2009-02-19 Composition for modulating stem cell growth with prostaglandins

Country Status (16)

Country Link
US (2) US8871752B2 (enExample)
EP (2) EP2656845A1 (enExample)
JP (1) JP2011512323A (enExample)
KR (1) KR20100119803A (enExample)
CN (2) CN102014921A (enExample)
AR (1) AR073158A1 (enExample)
AU (1) AU2009216067B2 (enExample)
BR (1) BRPI0907831A2 (enExample)
CA (1) CA2715486A1 (enExample)
IL (1) IL207652A0 (enExample)
MX (1) MX2010009131A (enExample)
NZ (1) NZ587348A (enExample)
RU (1) RU2010138603A (enExample)
TW (1) TW200942614A (enExample)
WO (1) WO2009104807A1 (enExample)
ZA (1) ZA201006125B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533445A1 (en) * 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
KR101171912B1 (ko) 2010-11-29 2012-08-07 기아자동차주식회사 밸브브릿지 일체형 가변 밸브 액츄에이터
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US20140371304A1 (en) * 2013-06-13 2014-12-18 Sucampo Ag Method for suppressing tumorigenicity of stem cells
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
JP2019513010A (ja) * 2016-03-04 2019-05-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
AU2018280264B2 (en) 2017-06-09 2024-07-11 Myoforte Therapeutics, Inc. Compositions and methods for preventing or treating muscle conditions
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
EP0857718B1 (en) * 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
AU2001239551B8 (en) * 2000-03-24 2005-11-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US8202909B2 (en) 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
JP4557288B2 (ja) * 2005-01-28 2010-10-06 アイシン・エィ・ダブリュ株式会社 画像認識装置及び画像認識方法、並びにそれを用いた位置特定装置、車両制御装置及びナビゲーション装置
EP1853271B1 (en) * 2005-03-04 2010-12-01 Sucampo AG Method and composition for treating peripheral vascular diseases
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2007070964A1 (en) 2005-12-22 2007-06-28 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
WO2008108322A2 (en) 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
FI20075417A0 (fi) 2007-06-05 2007-06-05 Marjo-Riitta Suuronen Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen

Also Published As

Publication number Publication date
WO2009104807A1 (en) 2009-08-27
MX2010009131A (es) 2010-12-06
RU2010138603A (ru) 2012-03-27
CN102014921A (zh) 2011-04-13
BRPI0907831A2 (pt) 2017-04-11
IL207652A0 (en) 2010-12-30
KR20100119803A (ko) 2010-11-10
TW200942614A (en) 2009-10-16
NZ587348A (en) 2012-04-27
JP2011512323A (ja) 2011-04-21
EP2656845A1 (en) 2013-10-30
US20150005381A1 (en) 2015-01-01
AU2009216067A1 (en) 2009-08-27
AR073158A1 (es) 2010-10-20
US20090209643A1 (en) 2009-08-20
CN104248638A (zh) 2014-12-31
ZA201006125B (en) 2011-05-25
US8871752B2 (en) 2014-10-28
EP2303278A1 (en) 2011-04-06
AU2009216067B2 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
AU2009216067B2 (en) Composition for modulating stem cell growth with prostaglandins
JP2004519412A (ja) １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
RU2548762C2 (ru) Способ и композиция для лечения дегенерации желтого пятна
US20080207759A1 (en) Method for protecting mitochondria
US20100305203A1 (en) Method for modulating claudin mediated functions
JP2017222708A (ja) 統合失調症の処置方法
US8569279B2 (en) Method for modulating claudin mediated functions
WO2016067620A1 (en) Method and composition for treating nonerosive reflux disease
EP3035925A1 (en) Method for treating neuropathic pain
WO2014200117A1 (en) Method for suppressing tumorigenicity of stem cells
US20120277299A1 (en) Method for modulating ion transporter

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140212

FZDE Discontinued

Effective date: 20160824